The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1687)

Abstract

Antisense oligonucleotides (AONs) hold great promise for therapeutic splice-switching correction in many genetic diseases and in particular for Duchenne muscular dystrophy (DMD), where AONs can be used to reframe the dystrophin transcript and give rise to a partially deleted but yet functional dystrophin protein. Many different chemistries of AONs can be used for splice switching modulation, and some of them have been evaluated in clinical trials for DMD. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake, and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to restore the expression of dystrophin in all relevant tissues and international efforts are currently on going to develop new compounds or alternative chemistries with higher therapeutic potential. Here, we describe the methods to evaluate the potency of antisense oligonucleotides, and in particular of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration. We focus on the most widely used mouse model for DMD, the mdx mouse and detail methods to analyze the skipping of the mouse exon 23 both in vitro in H2K mdx cells and in vivo in the mdx mouse model.

Key words

Antisense oligonucleotides (AONs) Splice-switching approaches Exon skipping Tricyclo-DNA Duchenne muscular dystrophy 

Notes

Acknowledgment

This work was supported by the Agence nationale de la recherche [Chair of Excellence HandiMedEx]; the Institut National de la santé et la recherche médical (INSERM); the Association Monegasque contre les myopathies (AMM); and the Duchenne Parent project France (DPPF).

References

  1. 1.
    McClorey G, Wood MJ (2015) An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 24:52–58CrossRefPubMedGoogle Scholar
  2. 2.
    Goyenvalle A, Griffith G, Babbs A, El Andaloussi S, Ezzat K, Avril A, Dugovic B, Chaussenot R, Ferry A, Voit T et al (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 21:270–275CrossRefPubMedGoogle Scholar
  3. 3.
    Goyenvalle A, Leumann C, Garcia L (2016) Therapeutic potential of tricyclo-DNA antisense oligonucleotides. J Neuromuscul Dis 3:157–167CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, Jat PS, Noble MD, Farmer K, Partridge TA (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162:486–498CrossRefPubMedGoogle Scholar
  5. 5.
    Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Høg A, Worm J, Hedtjärn M, Souleimanian N, Miller P et al (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38:e3CrossRefPubMedGoogle Scholar
  6. 6.
    Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81:1189–1192CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  1. 1.U1179 INSERM, UFR des Sciences de la Santé—LIA BAHN CSMUniversité de Versailles St-Quentin en YvelinesMontigny le BretonneuxFrance
  2. 2.SQY Therapeutics, UFR des Sciences de la SantéUniversité de Versailles Saint-Quentin en YvelinesMontigny-le-BretonneuxFrance

Personalised recommendations